AC Immune SA is to acquire a candidate vaccine and other assets to treat Parkinson’s disease in a strategic move to broaden its portfolio of drugs for the treatment of neurodegenerative diseases. The Switzerland-based company already has a portfolio of candidate drugs for Alzheimer’s disease. The acquisition – from Affiris AG of Austria – will give it a vaccine for Parkinson’s disease which has been validated in a Phase 1 clinical trial.
